Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
Delmas, Pierre D × McClung, Michael R Zanchetta, Jose R Racewicz, Artur Roux, Christian Benhamou, Claude-Laurent Mang, Zulema Eusebio, Rachelle A Beary, John F Burgio, David E Matzkin, Ellen Boonen, Steven #
Elsevier science inc
Bone vol:42 issue:1 pages:36-42
Introduction: Risedronate has been shown to be effective in the treatment of postmenopausal osteoporosis when given orally in daily or weekly doses or on 2 consecutive days per month. This randomized, double-blind, multi-center study was designed to assess the efficacy and safety of a single 150 mg risedronate once-a-month oral dose compared with the 5 mg daily regimen.